Comparison of the In Vitro Activity of the Glycylcycline Tigecycline (Formerly GAR-936) with Those of Tetracycline, Minocycline, and Doxycycline against Isolates of Nontuberculous Mycobacteria

ABSTRACT We compared the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, doxycycline, and minocycline by broth microdilution against 76 isolates belonging to seven species of rapidly growing mycobacteria (RGM) and 45 isolates belonging to five species of slowly growing nontuberculous mycobacteria (NTM). By using a resistance breakpoint of >4 μg/ml for tigecycline and >8 μg/ml for tetracycline, all RGM were highly susceptible to tigecycline, with inhibition of 50% of isolates at ≤0.12 μg/ml and inhibition of 90% of isolates at 0.25 μg/ml for Mycobacterium abscessus and inhibition of both 50 and 90% of isolates at ≤0.12 μg/ml for M. chelonae and the M. fortuitum group. The MICs of tigecycline were the same for tetracycline-resistant and -susceptible strains, and RGM isolates were 4- to 11-fold more susceptible to tigecycline than to the tetracyclines. In contrast, no slowly growing NTM were susceptible to tigecycline, and isolates of M. marinum and M. kansasii were less susceptible to this agent than to minocycline. This new antimicrobial offers exciting therapeutic potential for the RGM, especially for isolates of the M. chelonae-M. abscessus group, against which the activities of the currently available drugs are limited.

[1]  R. Wallace,,et al.  Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms , 1992, Antimicrobial Agents and Chemotherapy.

[2]  Kenneth,et al.  Mycobacterium wolinskyi sp. nov. and Mycobacterium goodii sp. nov., two new rapidly growing species related to Mycobacterium smegmatis and associated with human wound infections: a cooperative study from the International Working Group on Mycobacterial Taxonomy. , 1999, International journal of systematic bacteriology.

[3]  G. Eliopoulos,et al.  In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive Bacteria , 2000, Antimicrobial Agents and Chemotherapy.

[4]  A. Clément,et al.  Mycobacterial lung disease in cystic fibrosis: a prospective study. , 1997, The Pediatric infectious disease journal.

[5]  R. Wallace,,et al.  PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria , 1995, Journal of clinical microbiology.

[6]  N. Jacobus,et al.  In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines , 1993, Antimicrobial Agents and Chemotherapy.

[7]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[8]  R. Wallace,,et al.  Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism , 1993, Journal of clinical microbiology.

[9]  C Thornsberry,et al.  Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae , 1985, Antimicrobial Agents and Chemotherapy.

[10]  R. Wallace,,et al.  Human disease due to Mycobacterium smegmatis. , 1988, The Journal of infectious diseases.

[11]  M. Roberts,et al.  Tetracycline resistance determinants in Mycobacterium and Streptomyces species , 1994, Antimicrobial Agents and Chemotherapy.

[12]  R. Wallace,,et al.  Diagnosis and treatment of disease caused by nontuberculous mycobacteria. , 1990, The American review of respiratory disease.

[13]  R. Wallace,,et al.  Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. , 1981, Reviews of infectious diseases.

[14]  C. Cannon,et al.  Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? , 2000, American journal of respiratory and critical care medicine.

[15]  Frank,et al.  Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis , 1993, Journal of clinical microbiology.

[16]  R. Wallace,,et al.  Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. , 1985, The Journal of infectious diseases.

[17]  E. Goldstein,et al.  Comparative In Vitro Activities of GAR-936 against Aerobic and Anaerobic Animal and Human Bite Wound Pathogens , 2000, Antimicrobial Agents and Chemotherapy.

[18]  R. Wallace,,et al.  Mycobacterium immunogenum sp. nov., a novel species related to Mycobacterium abscessus and associated with clinical disease, pseudo-outbreaks and contaminated metalworking fluids: an international cooperative study on mycobacterial taxonomy. , 2001, International journal of systematic and evolutionary microbiology.

[19]  R. Wallace,,et al.  Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria , 1996, Antimicrobial agents and chemotherapy.

[20]  W. Craig,et al.  In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria , 2000, Antimicrobial Agents and Chemotherapy.

[21]  R. Wallace,,et al.  Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. , 1992, The Journal of infectious diseases.

[22]  G. Ellestad,et al.  Glycylcyclines: a new generation of tetracyclines. , 1995, The Journal of antimicrobial chemotherapy.